Literature DB >> 1506634

Liver damage from flucloxacillin, cloxacillin and dicloxacillin.

R Olsson1, B E Wiholm, C Sand, L Zettergren, R Hultcrantz, M Myrhed.   

Abstract

We describe a case of severe cholestatic liver disease, which persisted for 7 years, and was probably induced by flucloxacillin. We also report a survey of 77 liver reactions which were probably or possibly induced by penicillinase-resistant penicillins and spontaneously reported to the Swedish Adverse Drug Reactions Advisory Committee. The reactions were usually cholestatic with a tendency to a protracted course. There is some evidence for an immunoallergic idiosyncratic reaction. The incidence of reported liver reactions was estimated from sales data to be 1.6-2.9 per million DDD (defined daily doses) or, for flucloxacillin 1:11,000-1:30,000 prescriptions. Female sex, age and high daily doses seemed to be associated with higher risk of liver reactions from flucloxacillin.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1506634     DOI: 10.1016/0168-8278(92)90029-o

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  22 in total

1.  Risk of cholestatic liver disease associated with flucloxacillin and flucloxacillin prescribing habits in the UK: cohort study using data from the UK General Practice Research Database.

Authors:  Stefan Russmann; James A Kaye; Susan S Jick; Hershel Jick
Journal:  Br J Clin Pharmacol       Date:  2005-07       Impact factor: 4.335

2.  Drug-induced liver injury: Asia Pacific Association of Study of Liver consensus guidelines.

Authors:  Harshad Devarbhavi; Guruprasad Aithal; Sombat Treeprasertsuk; Hajime Takikawa; Yimin Mao; Saggere M Shasthry; Saeed Hamid; Soek Siam Tan; Cyriac Abby Philips; Jacob George; Wasim Jafri; Shiv K Sarin
Journal:  Hepatol Int       Date:  2021-02-27       Impact factor: 6.047

3.  The natural history of histologically proved drug induced liver disease.

Authors:  P G Aithal; C P Day
Journal:  Gut       Date:  1999-05       Impact factor: 23.059

Review 4.  Comparative tolerability of the newer fluoroquinolone antibacterials.

Authors:  P Ball; L Mandell; Y Niki; G Tillotson
Journal:  Drug Saf       Date:  1999-11       Impact factor: 5.606

Review 5.  Genomics and drug response.

Authors:  Liewei Wang; Howard L McLeod; Richard M Weinshilboum
Journal:  N Engl J Med       Date:  2011-03-24       Impact factor: 91.245

Review 6.  Antibacterial-induced hepatotoxicity. Incidence, prevention and management.

Authors:  D K George; D H Crawford
Journal:  Drug Saf       Date:  1996-07       Impact factor: 5.606

7.  Postoperative liver enzyme abnormalities are related to staged restorative proctocolectomy.

Authors:  Amosy E M'Koma; Walter E Longo
Journal:  Int J Colorectal Dis       Date:  2006-04-01       Impact factor: 2.571

8.  Risk factors for development of flucloxacillin associated jaundice.

Authors:  C K Fairley; J J McNeil; P Desmond; R Smallwood; H Young; A Forbes; P Purcell; I Boyd
Journal:  BMJ       Date:  1993-01-23

Review 9.  Genotyping for severe drug hypersensitivity.

Authors:  Eric Karlin; Elizabeth Phillips
Journal:  Curr Allergy Asthma Rep       Date:  2014-03       Impact factor: 4.806

10.  HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin.

Authors:  Ann K Daly; Peter T Donaldson; Pallav Bhatnagar; Yufeng Shen; Itsik Pe'er; Aris Floratos; Mark J Daly; David B Goldstein; Sally John; Matthew R Nelson; Julia Graham; B Kevin Park; John F Dillon; William Bernal; Heather J Cordell; Munir Pirmohamed; Guruprasad P Aithal; Christopher P Day
Journal:  Nat Genet       Date:  2009-05-31       Impact factor: 38.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.